SynthesisOncotarget2016
Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis.Oncotarget · 2017Pooled it
- Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells.Journal of Cancer · 2026Article
- Differential expression analysis identifies a prognostically significant extracellular matrix-enriched gene signature in hyaluronan-positive clear cell renal cell carcinoma.Scientific reports · 2024Article
- Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons.International journal of molecular sciences · 2023Review
- Expression of Components of the Renin-Angiotensin System by Cancer Stem Cells in Renal Clear Cell Carcinoma.Biomolecules · 2021Article
- Cancer Stem Cells-Key Players in Tumor Relapse.Cancers · 2021Review
- Steroid receptor RNA activator inhibits the migration, invasion and stemness characteristics of renal cell carcinoma cells.International journal of molecular medicine · 2020Article
- Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.Cells · 2020Review
- Stem/progenitor cell marker expression in clear cell renal cell carcinoma: a potential relationship with the immune microenvironment to be explored.BMC cancer · 2020Article
- Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma.Cancer science · 2020Article
- The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness.Cancers · 2020Review
- Extracellular Vesicles and Carried miRNAs in the Progression of Renal Cell Carcinoma.International journal of molecular sciences · 2019Review
- Article
- Prognostic Value of CD133 and SOX2 in Advanced Cancer.Journal of oncology · 2019Article
- Targeting Cancer Stem Cells to Overcome Chemoresistance.International journal of molecular sciences · 2018Review
- Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma.Cancer biomarkers : section A of Disease markers · 2018Article
- p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.Critical reviews in oncogenesis · 2018Review
- Biomarker discovery for renal cancer stem cells.The journal of pathology. Clinical research · 2018Review
- Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy.Pharmacology & therapeutics · 2017Review
- Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage.Oncogenesis · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRelevant markers of CSCs may serve as prognostic biomarkers of RCC. However, their actual prognostic significance remains inconclusive. Thus, a meta-analysis was performed to reevaluate the association of CSCs-relevant markers (CXCR4, CD133, CD44, CD105) expression with RCC prognosis more precisely.
methodsPubMed and Embase were searched to look for eligible studies. The pooled hazard ratios (HR) with 95% confidence intervals (95% CI) were used to reassess the association of CSCs markers expression and RCC prognosis of overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and progression-free survival (PFS).
resultsThere were 25 relevant articles, encompassing 2673 RCC patients, eligible for meta-analysis. Overall pooled analysis suggested that high CSCs markers expression predicted poor OS (HR, 2.10, 95% CI: 1.73-2.55) and DFS (HR, 3.77, 95% CI: 2.30-6.19). High CXCR4 expression predicted worse OS (HR, 2.57, 95% CI: 1.95-3.40), CSS (HR,1.97, 95% CI: 1.50-2.59), and DFS (HR, 5.82, 95% CI: 3.01-11.25). CD44 over-expression correlated with a poor OS(HR,1.58, 95% CI: 1.14-2.18), CSS (HR, 2.58, 95% CI: 1.27-5.23), and DFS (HR, 4.49, 95% CI: 2.12-9.53) in RCC patients. CD133 was an independent favorable prognostic factor for CSS (HR, 0.4, 95% CI: 0.29-0.54).
conclusionsThe presence of CSCs markers correlates with poor RCC outcome. CSCs may be potentially utilized as prognostic markers to stratify RCC patients, probably representing also a novel potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.